Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: Communication from the SSC of the ISTH

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 7, 2015, Pages 1345-1350

  Bodo I ^a   Eikenboom, J ^b   Montgomery, R ^c   Patzke, J ^d   Schneppenheim, R ^e   Di Paola, J ^f   Baronciani L , ^g   Bonomi A B , ^h,l   Budde U , ^e   Castaman G , ⁱ   Federici A B , ^c,j   Friedman K D , ^k   Lawrie A , ^g   Peyvandi F , ^h   Sadler J E , ^m  

^a Szent Laszlo Hospital   (Hungary)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Siemens Healthcare Diagnostics Products GmbH   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF COLORADO   (United States)

^g MAGGIORE HOSPITAL   (Italy)

^h Hemophilia and Thrombosis Center   (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j Angelo Bianchi Bonomi Hemophilia Thrombosis Center   (Italy)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF MILAN   (Italy)

^m WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IB; MONOCLONAL ANTIBODY; RISTOCETIN; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER;

ANTIGEN BINDING; ARTICLE; AUTOMATION; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; HUMAN; NOMENCLATURE; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE; BLOOD; CHEMISTRY; CLASSIFICATION; CONSENSUS; IMMUNOASSAY; PRACTICE GUIDELINE; PREDICTIVE VALUE; REPRODUCIBILITY; STANDARDS; THROMBOCYTE;

BIOMARKERS; BLOOD PLATELETS; CONSENSUS; FLOW CYTOMETRY; HUMANS; IMMUNOASSAY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TERMINOLOGY AS TOPIC; VON WILLEBRAND FACTOR;

EID: 84935687838     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12964     Document Type: Article

References (63)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
2. Howard MA, Firkin BG. Ristocetin-a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-9.
3. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52: 2708-16.
4. Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975; 85: 318-28.
5. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
6. Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006; 32: 456-71.
7. Bolton-Maggs PH, Favaloro EJ, Hillarp A, Jennings I, Kohler HP. Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders. Haemophilia 2012; 18(Suppl. 4): 66-72.
8. Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013; 122: 3735-40.
9. Castaman G, Hillarp A, Goodeve A. Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis. Haemophilia 2014; 20(Suppl. 4): 65-70.
10. Hayward CP, Moffat KA, Graf L. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges. Int J Lab Hematol 2014; 36: 334-40.
11. Pruthi RK. A practical approach to genetic testing for von Willebrand disease. Mayo Clin Proc 2006; 81: 679-91.
12. Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology 1997; 29: 385-91.
13. Rodeghiero F, Castaman G. Calibration of lyophilized standards for ristocetin cofactor activity of von Willebrand Factor (vWF) requires vWF-deficient plasma as diluent for dose-response curves. Thromb Haemost 1987; 58: 978-81.
14. Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010; 8: 2842-4.
15. Hillarp A, Stadler M, Haderer C, Weinberger J, Kessler CM, Romisch J. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost 2010; 8: 2216-23.
16. Chen D, Daigh CA, Hendricksen JI, Pruthi RK, Nichols WL, Heit JA, Owen WG. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost 2008; 6: 323-30.
17. Lindahl TL, Fagerberg IH, Larsson A. A new flow cytometric method for measurement of von Willebrand factor activity. Scand J Clin Lab Invest 2003; 63: 217-23.
18. Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica 2007; 92: 1647-54.
19. Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009; 7: 1832-9.
20. Patzke J, Schneppenheim R. Laboratory diagnosis of von Willebrand disease. Hamostaseologie 2010; 30: 203-6.
21. Favaloro EJ. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis 2011; 22: 553-64.
22. Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 1991; 266: 8149-55.
23. Weiss HJ, Rogers J, Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J Clin Invest 1973; 52: 2697-707.
24. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116: 280-6.
25. de Maistre E, Volot F, Mourey G, Aho LS, Ternisien C, Briquel ME, Bertrand MA, Tardy B, Frotscher B, Nguyen P, Dumont L, Vandroux D, Hezard N, Trossaert M. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance. Thromb Haemost 2014; 112: 825-30.
26. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-13.
27. Vanhoorelbeke K, Pareyn I, Schlammadinger A, Vauterin S, Hoylaerts MF, Arnout J, Deckmyn H. Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA. Thromb Haemost 2005; 93: 165-71.
28. Vanhoorelbeke K, Cauwenberghs N, Vandecasteele G, Vauterin S, Deckmyn H. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease. Semin Thromb Hemost 2002; 28: 161-6.
29. Federici AB, Canciani MT, Forza I, Mannucci PM, Marchese P, Ware J, Ruggeri ZM. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels. Haematologica 2004; 89: 77-85.
30. Costa-Pinto J, Perez-Rodriguez A, del C Goméz-del-Castillo M, Loures E, Rodriguez-Trillo A, Batlle J, Lopez-Fernandez MF. Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies. Haemophilia 2014; 20: 559-67.
31. Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia 2014; 20: 147-53.
32. Cabrera N, Moret A, Caunedo P, Cid AR, Vila V, Espana F, Aznar JA. Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method. Haemophilia 2013; 19: 920-5.
33. Verfaillie CJ, De Witte E, Devreese KM. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease. Int J Lab Hematol 2013; 35: 555-65.
34. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011; 117: e67-74.
35. Patzke J, Budde U, Huber A, Mendez A, Muth H, Obser T, Peerschke E, Wilkens M, Schneppenheim R. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. Blood Coagul Fibrinolysis 2014; 25: 860-70.
36. Lawrie AS, Stufano F, Canciani MT, Mackie IJ, Machin SJ, Peyvandi F. A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia 2013; 19: 338-42.
37. Geisen U, Zieger B, Nakamura L, Weis A, Heinz J, Michiels JJ, Heilmann C. Comparison of von Willebrand factor (VWF) activity VWF: Ac with VWF ristocetin cofactor activity VWF:RCo. Thromb Res 2014; 134: 246-50.
38. Graf L, Moffat KA, Carlino SA, Chan AK, Iorio A, Giulivi A, Hayward CP. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. Int J Lab Hematol 2014; 36: 341-51.
39. Patzke J, Muth H, Wilkens M, Schneppenheim R. Performance of a new automated von Willebrand factor activity assay based in GPIbα binding. J Thromb Haemost 2011; 9: 671. Abstract P-WE-479.
40. ISTH. SSC Subcommittee minutes 2014: von Willebrand factor. International Society on Thrombosis and Haemostasis. 2014; http://c.ymcdn.com/sites/www.isth.org/resource/resmgr/yearly_subcommittee_minutes/all_subcommittee, _standing_c.pdf. Accessed 30 November 2014.
41. Stufano F, Baronciani L, Pagliari MT, Franchi F, Cozzi G, Garcia Oya I, Peyvandi F. Diagnosis of type 2B von Willebrand disease (VWD) using an alternative assay to ristocetin induced platelet agglutination (RIPA). Thromb Res 2014; 134: OC-156.
42. Goodall AH, Jarvis J, Chand S, Rawlings E, O'Brien DP, McGraw A, Hutton R, Tuddenham EG. An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope. Br J Haematol 1985; 59: 565-77.
43. Chand S, McCraw A, Hutton R, Tuddenham EG, Goodall AH. A two-site, monoclonal antibody-based immunoassay for von Willebrand factor-demonstration that vWF function resides in a conformational epitope. Thromb Haemost 1986; 55: 318-24.
44. Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-7.
45. Laffan M, Brown SA, Collins PW, Cumming AM, Hill FG, Keeling D, Peake IR, Pasi KJ. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 199-217.
46. Favaloro EJ, Henniker A, Facey D, Hertzberg M. Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost 2000; 84: 541-7.
47. De Vleeschauwer A, Devreese K. Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17: 353-8.
48. Sucker C, Senft B, Scharf RE, Zotz RB. Determination of von Willebrand factor activity: evaluation of the HaemosIL assay in comparison with established procedures. Clin Appl Thromb Hemost 2006; 12: 305-10.
49. Salem RO, van Cott EM. A new automated screening assay for the diagnosis of von Willebrand disease. Am J Clin Pathol 2007; 127: 730-5.
50. Pinol M, Sales M, Costa M, Tosetto A, Canciani MT, Federici AB. Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease. Haematologica 2007; 92: 712-3.
51. Trossaert M, Ternisien C, Lefrancois A, Llopis L, Goudemand J, Sigaud M, Fouassier M, Caron C. Evaluation of an automated von Willebrand factor activity assay in von Willebrand disease. Clin Appl Thromb Hemost 2011; 17: E25-9.
52. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood 2005; 106: 3035-42.
53. ISTH. SSC Subcommittee minutes 2011: von Willebrand factor. International Society on Thrombosis and Haemostasis. 2011; http://c.ymcdn.com/sites/www.isth.org/resource/resmgr/yearly_subcommittee_minutes/2011_minutes.pdf. Accessed 30 November 2014.
54. Bowyer AE, Shepherd F, Kitchen S, Makris M. A rapid, automated VWF ristocetin cofactor activity assay improves reliability in the diagnosis of von Willebrand disease. Thromb Res 2011; 127: 341-4.
55. Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia 2011; 17: 252-6.
56. Miller CH, Platt SJ, Daniele C, Kaczor D. Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2002; 88: 56-9.
57. Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000). Blood Coagul Fibrinolysis 2004; 15: 505-11.
58. Redaelli R, Corno AR, Borroni L, Mostarda G, Nichelatti M, Morra E, Baudo F. von Willebrand factor ristocetin cofactor (VWF:RCo) assay: implementation on an automated coagulometer (ACL). J Thromb Haemost 2005; 3: 2684-8.
59. Zhao Y, Gu Y, Ji S, Yang J, Yu Z, Ruan C. Development of an ELISA method for testing VWF ristocetin cofactor activity with improved sensitivity and reliability in the diagnosis of von Willebrand disease. Eur J Haematol 2012; 88: 439-45.
60. Pinol M, Sanchez T, Sales M, Vanrusselt M, Arnout J. New automated ristocetin cofactor activity assay to distinguish type 1 and type 2 von Willebrand disease (VWD). J Thromb Haemost 2009; 7: Abstract PP-Th-635.
61. Tous J, Barry RG, Arnout J, Vanrusselt M, Pascual Z. New automated chemiluminescent VWF:Ag and VWF:RCo assays: preliminary analytical and clinical performance. J Thromb Haemost 2009; 7: Abstract PP-TH-625.
62. Schneppenheim R, Obser T, Budde U, Patzke J. Development of a newfunctional assay for von Willebrand factor binding to platelet GpIba that does not require Ristocetin. Hamostaseologie 2010; 30: FC4-05.
63. Favaloro EJ, Mohammed S. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. Thromb Res 2014; 134: 1292-300.